Enhanced tDCS for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a potential new therapy for Alzheimer's Disease (AD) using transcranial direct current stimulation (tDCS), which delivers a small electrical current to the brain. Researchers are testing whether a higher intensity of tDCS at 4mA, compared to the usual 2mA, can more effectively improve symptoms. The trial includes three groups: one receiving 4mA, one with 2mA, and a sham group receiving a placebo treatment. It is suitable for individuals with mild to moderate Alzheimer's who have not experienced strokes or traumatic brain injuries and do not have metal implants. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in Alzheimer's treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that transcranial direct current stimulation (tDCS) is safe for Alzheimer's Disease?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe and well-tolerated. A review of studies found that tDCS usually causes mild side effects like tingling and itching, which are temporary and not serious. Other research supports that tDCS is a noninvasive method to stimulate the brain and is considered safe. While mild sensations may occur during treatment, serious side effects are rare. Overall, tDCS has proven to be a safe option for people with conditions like Alzheimer's Disease.12345
Why are researchers excited about this trial?
Unlike traditional treatments for Alzheimer's, which often involve medications targeting neurotransmitter imbalances, transcranial direct current stimulation (tDCS) offers a non-invasive brain stimulation technique. Researchers are excited about tDCS because it uses low electrical currents to potentially enhance brain function and improve cognitive symptoms associated with Alzheimer's. The treatment's unique delivery method—through electrodes placed on the scalp—makes it distinct from oral medications and may offer fewer side effects. Additionally, the trial's experimental arms explore different stimulation intensities (4mA vs. 2mA), which could provide insights into optimizing the effectiveness of this innovative approach.
What evidence suggests that this trial's treatments could be effective for Alzheimer's Disease?
Research has shown that transcranial direct current stimulation (tDCS) can improve thinking and memory in people with Alzheimer's Disease (AD). Studies have found that tDCS enhances overall thinking skills and memory, especially in tasks like remembering words. In one review, people with AD showed more improvement than those with mild cognitive impairment (MCI) or other types of dementia. Anodal tDCS, which boosts brain activity, proved more effective than other types of stimulation. Multiple tDCS sessions also seem to aid memory improvements. These findings suggest that tDCS could be a promising method for improving symptoms in people with Alzheimer's. This trial will compare different stimulation intensities, including 4mA and 2mA, as well as a sham stimulation, to evaluate their effectiveness in enhancing cognitive function in AD patients.26789
Are You a Good Fit for This Trial?
This trial is for individuals with mild to moderate Alzheimer's Disease, who score between 18 and 25 on the MoCA test, indicating their cognitive abilities. They must also have a certain score on the Cambridge Naming Task. People with significant heart disease, alcohol or drug abuse history, stroke or traumatic brain injury (TBI), or those with shunts or metal in their body cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcranial direct current stimulation (tDCS) at either 2mA or 4mA to test the effectiveness in improving naming ability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- transcranial direct current stimulation
transcranial direct current stimulation is already approved in United States, European Union for the following indications:
- Investigational for Alzheimer's Disease and Frontotemporal dementia
- Investigational for Alzheimer's Disease and other neurological conditions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baycrest
Lead Sponsor
Alzheimer's Society
Collaborator